Wire Stories

SEOUL, South Korea--(BUSINESS WIRE)--South Korea's popular singer Lee HongKi has released his new track and mint as music NFT on…

2 years ago

China Eastern livestream brings together Chinese and Italian university students at first day of Wenzhou-Rome direct flight

SHANGHAI--(BUSINESS WIRE)--On October 27 China Eastern Airlines (CEA) launched a direct flight between Whenzhou, China and Rome, Italy. From then…

2 years ago

Sino-German “Generation Z” Uncover In-flight Meals with CEA Chefs

SHANGHAI--(BUSINESS WIRE)--On October 28, teachers and students from Chinese and German universities participated in the livestream activity hosted by China…

2 years ago

Quarterly EPS Increases 23% to $0.85 from $0.69 for the Preceding Quarter Quarterly Return on Average Assets Increases to 1.51%…

2 years ago

Bitcoin.com Officially Expands Access to DeFi with Public Sale of Ecosystem Utility Token VERSE

Whitelisted individuals for the sale will be able to purchase VERSE tokens using BTC, BCH, ETH and USDT/USDC. SAINT KITTS…

2 years ago

New Vonage Study Reveals That Consumers Want Digital Interactions With Brands to Feel More Like Personal Conversations

Vonage 11th Annual Global Customer Engagement Report reveals technology gap prevents meaningful connections and risks loyalty among customers SINGAPORE--(BUSINESS WIRE)--Vonage,…

2 years ago

Eucure Biopharma, a Subsidiary of Biocytogen, Announces Partnership with ISU ABXIS for the Development of Tri-specific Antibodies using YH003 Antibody Sequence

YH003 is an agonistic anti-CD40 IgG2 monoclonal antibody with best-in-class potential YH003 in combination with PD-1 are being dosed in…

2 years ago

Eucure Biopharma, a Subsidiary of Biocytogen, Announces Partnership with ISU ABXIS for the Development of Tri-specific Antibodies using YH003 Antibody Sequence

YH003 is an agonistic anti-CD40 IgG2 monoclonal antibody with best-in-class potential. YH003 in combination with PD-1 are being dosed in…

2 years ago

MELBOURNE, Australia--(BUSINESS WIRE)--Global fintech Airwallex has embarked on a pivotal partnership with the University of Melbourne, which will help build…

2 years ago

Orum Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of ORM-5029 in Development to Treat HER2-Expressing Advanced Solid Tumors

ORM-5029 is a first-in-class drug candidate designed to selectively deliver catalytic GSPT1 protein degraders to HER2-expressing tumor cells via antibody…

2 years ago
Show more Posts
Show previous Posts